ArticleAsia-Pacific journal of clinical oncology2026

Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy.

Junipearl Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.